Extract C: Funding preventative genomic health screenings

Since the late 2010s, the debate over how to fund preventative genomic health screenings in the UK has intensified. While the NHS subsidises targeted screening for a narrow range of high-risk genetic conditions, citizens still face high out-of-pocket fees for comprehensive whole-genome sequencing. Supporters of private fees argue that the direct private benefits of early genomic health profiling are substantial, leading to better-tailored personal nutrition, lifestyle choices, and early detection of treatable illnesses, which directly improves individual longevity and quality of life. They argue that because individuals directly reap these health dividends, private financial contributions are both fair and sustainable. Without fees, they claim, widespread public genomics programs would become an unsustainably expensive state-funded service that disproportionately subsidises higher-income, health-conscious demographics.

However, critics argue that market-rate pricing acts as a major barrier, preventing individuals from lower-income backgrounds from accessing life-saving preventative health technology. Despite these high costs, consumer demand among wealthier households has remained robust, yet significant inequalities in access to preventative healthcare persist.

Beyond the immediate individual health benefits, some health economists highlight the broader societal returns of early genomic diagnostics. They argue that a healthier population is a cornerstone of a highly productive, active workforce, which reduces long-term pressures on public services and lowers the future fiscal burden of chronic disease management on the NHS. Consequently, they describe preventative genomic screening as a "...service which, if left to the free market, will be significantly under-provided" (Extract C, lines 16–17).